Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Returning from recess today, the House is set to consider the $128 billion “minibus” approved by the Senate on November 1, HR 2112. It covers FDA, NSF, the National Institute of Standards and Technology (NIST), and the Office of Science and Technology Policy (OSTP). More information can be found here. NIH is arguably the most important science agency not covered by the minibus. President Barack Obama proposed a $200 million, or 3% increase, to $31.7 billion. Senate Appropriations had approved, on September 21, $30.5 billion for NIH, while House Appropriations proposed (but has not voted on) $31.7 billion for the agency. Experts wonder if a bill that matches Obama in NIH spending could survive a Republican-controlled House. What are your predictions?